Foundational Research The foundational research by Loren Pickart in the 1970s and 1980s established GHK's tissue repair properties and led to the development of copper peptide skincare products
UK patients should understand that: Available evidence is largely from Phase 2 studies with relatively short follow-up periods Long-term cardiovascular outcome data are not yet available for either agent Phase 3 trials are ongoing, and results will inform future regulatory submissions to the MHRA UK patients interested in accessing these treatments through clinical trials may wish to consult the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) or ClinicalTrials.gov for current recruitment opportunities
Skin barrier repair The skin barrier in psoriasis is functionally impaired
This guide covers everything: how GHK-Cu actually stimulates hair follicles, the optimal dosing protocols for injection and topical use, the critical role of microneedling in absorption, realistic timelines for results, and how to combine copper peptides with other treatments for maximum efficacy
Patients should not mix drugs or supplements in the same syringe
Topical reactions: rare irritation , redness or dryness , especially at 3 %+ percentages on sensitive skin
